Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test effective treatments. With so much less known about rare diseases than common ones, scientists may find themselves groping blindly trying to develop drugs and treatments.
Yet rare disease stocks do have some benefits over their common disease brethren. Special designations and tax benefits can be given to drugs that treat rare diseases, and the FDA can expedite approval if a drug serves an unmet need, such as curing an incurable disease or treating a rare one.
So for an investor keen to invest for clinical trials, here are 3 of the top rare disease stocks to buy.
This post appeared first on InvestorPlace.